key: cord-0813030-itv4j9q3
authors: McDonald, J. Tyson; Enguita, Francisco Javier; Taylor, Deanne; Griffin, Robert J.; Priebe, Waldemar; Emmett, Mark R.; Sajadi, Mohammad M.; Harris, Anthony D.; Clement, Jean; Dybas, Joseph M.; Aykin-Burns, Nukhet; Guarnieri, Joseph W.; Singh, Larry N.; Grabham, Peter; Baylin, Stephen B.; Yousey, Aliza; Pearson, Andrea N.; Corry, Peter M.; Saravia-Butler, Amanda; Aunins, Thomas R.; Sharma, Sadhana; Nagpal, Prashant; Meydan, Cem; Foox, Jonathan; Mozsary, Christopher; Cerqueira, Bianca; Zaksas, Viktorija; Singh, Urminder; Wurtele, Eve Syrkin; Costes, Sylvain V.; Davanzo, Gustavo Gastão; Galeano, Diego; Paccanaro, Alberto; Meinig, Suzanne L.; Hagan, Robert S.; Bowman, Natalie M; Wolfgang, Matthew C.; Altinok, Selin; Sapoval, Nicolae; Treangen, Todd J.; Moraes-Vieira, Pedro M.; Vanderburg, Charles; Wallace, Douglas C.; Schisler, Jonathan; Mason, Christopher E.; Chatterjee, Anushree; Meller, Robert; Beheshti, Afshin
title: The Great Deceiver: miR-2392’s Hidden Role in Driving SARS-CoV-2 Infection
date: 2021-08-18
journal: bioRxiv
DOI: 10.1101/2021.04.23.441024
sha: bad675c0075eadd7514b20968c43875f160de0c1
doc_id: 813030
cord_uid: itv4j9q3

MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provides an exciting avenue towards antiviral therapeutics. From patient transcriptomic data, we have discovered a circulating miRNA, miR-2392, that is directly involved with SARS-CoV-2 machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia as well as promoting many symptoms associated with COVID-19 infection. We demonstrate miR-2392 is present in the blood and urine of COVID-19 positive patients, but not detected in COVID-19 negative patients. These findings indicate the potential for developing a novel, minimally invasive, COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we have developed a novel miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters and may potentially inhibit a COVID-19 disease state in humans.

In Fall of 2019, the zoonotic spillover event led to the first known human infection with the 71 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent human-to-human 72 transmission triggered a pandemic leading to a worldwide health crisis from the resulting disease, 73 referred to as coronavirus disease 2019 (COVID-19) Zhu et al., 2020) . 74 COVID-19 causes substantial pulmonary disease but can also cause systemic health risks from 75 extrapulmonary manifestations. Its effects entangle the entire body including but not limited to the 1, miR-34a-5p, miR-30c-5p, miR-29b-3p, miR-124-3p, and miR-155-5p) and upregulation of a 141 single miRNA, miR-2392 (Fig. 1A) . Using IPA's downstream effects analysis to predict biological 142 processes from the combined suppression of the seven miRNAs and the upregulation of miR-2392 143 resulted in increased inflammation, immune suppression, and suppression of mitochondrial 144 activity in the BALF dataset ( Fig. 1B and 1C) . 145 In support of these findings, previous studies have shown upregulation of miR-10, miR-124, 153 We performed pathway analysis with miR-2392 targets to determine its potential impact on 154 the host. Upregulation of miR-2392 in the BALF RNA-seq dataset impacted many downstream 155 targets and pathways related to negative health outcomes (Fig. 1C) . This includes mitochondrial 156 suppression and activation of factors related to reactive oxygen species (ROS). Since it is known 157 that miR-2392 directly interacts with mitochondrial DNA (mtDNA) to inhibit the levels of 158 oxidative phosphorylation transcripts (Fan et al., 2019) , this could be a compensatory response to 159 the inhibition of mitochondrial bioenergetics. 160 Glycolytic pathways (Fig. 1C) are also upregulated in association with increased miR-2392. 161 MiR-2392 drives both hexokinase 2 (HK2) and pyruvate kinase (PKM), both of which positively 162 regulate glycolysis. HK2 produces a primary regulator of glycolysis, glucose-6-phosphate and 163 enhances GDP-glucose biosynthesis. GDP-glucose is a nucleotide sugar which an essential 164 substrate for all glycosylation reactions (i.e. glycosylation of viral spike proteins). PKM is essential 165 for the production of ATP in glycolysis that catalyzes the transfer of the phosphate group from 166 phosphoenolpyruvate to ADP to make ATP. The mechanism of how miR-2392 is driving these 167 pathways is not clearly understood, but one possibility could be stabilization of glycolytic 168 transcripts. 169 Overall, the observed upregulation of glycolysis and antiviral effects related to miR-2392 improving intracellular thiol redox ratio as a precursor for major thiol antioxidant glutathione (Ho 187 and Douglas, 1992) and inhibiting the NF-kB pathway (Poppe et al., 2017) . Inhibition of the NF- Demirci and Adan, 2020; Schult et al., 2018) . This has been shown to assist viral replication and 204 evasion of the immune system (Islam and Islam, 2021) . Thus, we analyzed the conservation of 205 human miR-2392 across species and the integration of miR-2392 into the SARS-CoV-2 genome 206 (Fig. 2) . 207 We determined the conservation of miR-2392 across different species using the UCSC 208 Genome Browser (Kent et al., 2002) . The mature 20 base-pair miR-2392 is derived from an 84 209 base-pair region of the 3´-UTR in the long non-coding RNA gene, maternally expressed 3 (MEG3) 210 and is located in an imprinted region DLK1-DIO3 that contains three clusters with 51 other 211 miRNAs ( Fig. 2A and 2B) . A basewise evolutionary comparison showed miR-2392 is highly 212 conserved among non-human primates such as dogs, cats, and ferrets, species known to be infected The impact of miR-2392's host gene, MEG3, within normal tissues was determined utilizing 216 GTEx data (Consortium, 2020) . For the majority of healthy tissues, MEG3 was either not detected 217 or being expressed at low levels (Fig. 2B) . This can imply that miR-2392 does not seem to 218 significantly affect normal tissues. 219 We used miRanda (Enright et al., 2003) to identify potential miR-2392 binding sites with 220 respect to the SARS-CoV-2 reference genome (Wuhan-Hu-1; NC045512.2) and lineages of 221 concern. The miR-2392 seeding region is heavily integrated and conserved in different viral strains 222 (Fig. 2C) . The three best scores are located in the NSP2, NSP3, and E-genes. Notably, these 223 regions were conserved among 6 concerning lineages represented by 14 recent genomes available 224 from the Global Initiative on Sharing All Influenza Data (GISAID, (Shu and McCauley, 2017) ).

MiR-2392 targets mitochondrial and inflammatory pathways associated with SARS-CoV-2 227 To determine a more comprehensive impact of miR-2392 affected pathways in COVID-19 228 patients, gene targets were predicted by seed-region base pairing in the miRmap database (Vejnar 229 and Zdobnov, 2012). This list was refined by overlap in several miRNA databases including (Fig. 3H) . This revealed 14 genes harboring miR-2392 seed 251 sequences that were significantly dysregulated in the nasal and heart samples. In nasal samples, 252 SLC25A28, a mitoferrin which mediates mitochondrial iron transport, was strongly upregulated 253 along with IBA57, which is involved in iron sulfur assembly. The mitochondrial outer membrane 254 protein import complex subunit TOMM20, cytochrome c oxidase (complex IV) subunit COX6B1, 255 and mitochondrial transcription factor COT-2 (NR2F2) were strongly downregulated. In the heart, 

Overexpression of miR-2392 simulates a phenotype similar to COVID-19 infection 290 To determine if miR-2392 upregulation would elicit effects similar to a COVID-19 infection, 291 cells were treated with a miR-2392 mimic. Using RNA-seq, 649 genes had a fold-change greater 292 than ±1.2 and a p-value less than 0.05 (Fig. 4A ) and many genes were miR-2392 predicted targets 293 (Fig. 4B) . These genes were then compared to whole cell proteome data from a human-derived overexpression. We also found miR-2392 overexpression impacted genes involved with 301 mitochondria and inflammation ( Fig. 4D-4F) . 302 To determine if there was a direct correlation between miR-2392 overexpression and SARS- treatment to the A549 and Calu-3 cells infected with SARS-CoV-2 ( Fig. 4G and 4H ) as well as 307 in lung biopsies post-mortem from two COVID-19 positive patients (Fig. 4H) . Using nasal swab 308 samples, there was a significant and positive correlation between patients with medium-and low-309 viral loads compared to non-infected patients ( Fig. 4I and 4J) . Additional miR-2392 correlation 310 to SARS-CoV-2 infections used RNA-seq data from multiple tissues (heart, kidney, liver, lymph 311 node, and lung) obtained during autopsies of COVID-19 patients with high or low viral loads ( Fig.   312 4I-J). There was a positive correlation to lung and lymph node tissues with miR-2392 expression.

Interestingly, there was a significant and positive correlation to liver tissue when comparing gene 314 fold-change values ( Fig. 4I) but not C2 curated biological genesets (Fig. 4J) . In contrast, a 315 negative correlation to heart tissue was observed.

Statistically significant pathways that were enriched due to miR-2392 treatment were 317 examined using fGSEA (Fig. 4K-O) . MiR-2392 treatment induced a pathway response that was 318 significantly related to SARS-CoV-2 pathways. One obvious relationship shows that the Reactome 319 SARS-CoV-2 pathways were significantly activated for the miR-2392 treated cells compared to 320 the controls ( Fig. 4K and 4L ). Significant Hallmark pathways (Fig. 4N) show upregulation of We observed a statistically significant increase of miR-2392 in COVID-19 positive patients 344 from both the serum and urine samples (Fig. 5A ). In addition, Receiver Operating Characteristic 345 (ROC) curve analysis revealed that miR-2392 is significantly associated with SARS-CoV-2 346 infection in patients (Fig. 5B ) in all tissues. MiR-2392 levels were higher for conditions associated 347 with infection of more severely affected patients (i.e. intubated or ICU) (Fig. 5C) . Interestingly, 348 low levels miR-2392 appeared in the nasopharyngeal location with no significant differences 349 occurring between seasonal coronavirus samples. To study more specific tissue origins for miR-350 2392 we infected monocytes obtained from healthy donors with SARS-CoV-2 reference strain (i.e. 351 strain from Wuhan) and also P1 variant (Fig. 5D) . We saw an increase of miR-2392 with the 352 reference SARS-CoV-2 infected cells and a significant increase in the P1 variant infected cells.

Previously, it was shown that these monocytes infected with SARS-CoV-2 have increased pro- We also quantified miR-1-3p ( Fig. S3) , miR-155-5p (Fig. S4) , and miR-124-3p ( Fig. S5 ) 359 which were predicted to be inhibited by COVID-19 infection (Fig. 1A) . MiR-1-3p and miR-155-360 5p were significantly suppressed in the serum with no differences in the urine or nasopharyngeal 361 samples ( Fig. S3 and S4 ). MiR-1-3p is known to be beneficial for cardiovascular functions, with 362 its inhibition leading to heart failure and disease (Condorelli et al., 2010). Interestingly, when 363 quantifying miR-1-3p in the SARS-CoV-2 infected monocytes we observe a significant decrease 364 with the reference strain, while no different with the P1 variant (Fig. S3D) . For miR-124-3p, we 365 observed very low amounts (on average < 2 copies/5 ng RNA), for all conditions, which indicates 366 that miR-124-3p is not circulating for any of the patients for any the conditions observed (Fig. S5) . 367 MiR-124-3p provides an ideal miRNA negative control candidate for SARS-COV-2. statistical differences in other groups were not present (Fig. 6H) . Virus titers from oropharyngeal 393 swabs for IN treatment were significantly lower (p = 0.018) than those from hamsters receiving 394 Nanoligomers IP or PBS on day 1 post-challenge, but there were no differences among groups on 395 days 2 and 3 post-challenge (Fig. 6I) . Although not statistically different than the control 396 treatment, the data indicates a downward trend with Nanoligomers treatment (Fig. 6J ) and the total 397 histopathological score for the IN was lower than the controls. COVID-19 viral loads compared to those without disease as predicted from RNA-seq data. The 445 expression of seven miRNAs was decreased (miR-10, miR-1, miR-34a-5p, miR-30c-5p, miR-29b-446 3p, miR-124-3p, and miR-155-5p) while a single miRNA, miR-2392, was significantly increased 447 ( Fig. 1) . This key miRNA signature was involved in major cellular and molecular mechanisms 448 that drives the viral-host response.

Upregulation of miR-10a-5p led to suppression of SDC1 defending against Porcine patients identified miR-146a, miR-21, miR-142, and miR-15b as potential biomarkers as well as 462 contributors to disease pathogenesis (Tang et al., 2020) . While these studies are limited to a 463 specific tissue, our data that correlates miRNA signatures from multiple tissues (Fig. 3) suggests 464 miR-2392 is a unique target that is ubiquitously involved in COVID-19 symptoms. To start 465 addressing the multi-tissue impact of miR-2392 we show that miR-2392 is overexpressed in 466 healthy monocyte cells infected with both the reference and P1 SARS-CoV-2 variants (Fig. 5D) . 467 This can indicate isolated cells will overexpress miR-2392 when infected with SARS-CoV-2 and 468 further work is currently being done to investigate multi-tissue behavior of miR-2392. dramatically highlighted in BALF samples (Fig. 1C) . In a study of tongue squamous cell OXPHOS genes (Fig. 1C) is also reflected in the down-regulation of the nuclear DNA coded 502 mitochondrial transcripts of the complex I and IV genes and the iron-sulfur and heme iron 503 complexes in the nasal, heart, and kidney autopsy samples (Fig. 3D) , mitochondrial inhibition by 504 miR-2392 appears to be the only physiological function that is common across all tissues in 505 infected individuals suggesting mitochondrial modulation is a central feature of SARS-CoV-2 506 pathophysiology.

The inhibition of mitochondrial genes by miR-2392 would impair OXPHOS, which would 508 have the most adverse effects on the high mitochondrial energetic tissues (brain, heart, kidney), (Fig. 1C) . Thus, SARS-CoV-2 induction of miR-2392 (Fig. 5) and its associated inhibition of 516 mtDNA and nuclear DNA OXPHOS genes ( Fig. 3 and S1 ) could explain many of the metabolic potential confounding diseases that may influence the expression of multiple miRNAs requires the 526 further evaluation of the targets found in this study (Fig. 5) . 527 Advances in RNA chemistry and delivery systems enabled the first miRNA-based agents to with three other miRNAs were made with miR-1-3p (Fig. S3) , miR-155-5p (Fig. S4) , and miR-650 124-3p (Fig. S5) . 822 Patient specimens were processed as described in Butler et al., 2020 (Butler et al., 2021) . 823 Briefly, nasopharyngeal swabs were collected using the BD Universal Viral Transport Media 

Human autopsy tissue collection for RNA-seq analysis 829 The full methods of the patient sample collection from the autopsy patients are currently route to target the pulmonary system, however there is concern that the blood filtering organs or 883 uptake in the endothelium may have blunted delivery directly to the lungs. inflammation score from the interstitial lung inflammation, and total histopathological 890 scores/assessment was made.

The dose of anti-miR-2392 that was used was calculated to raise blood levels to 10 M if it 892 were given intravenously. The dose was estimated from the average IC50s determined from our in (Bio-Rad) the following PCR reaction was used for all the primers: 1 cycle 95C for 5 min, 40 936 cycles of 95C for 30 sec and 58C for 1 min (the annealing temperature can change depending on 937 the primer), 1 cycle of 4C for 5 min, and 1 cycle of 90C for 5 min. Not all miRNA primers sets 938 for ddPCR will have the same annealing temperature, so optimizing the annealing temperature is 939 required for each primer set. Their respective annealing temperatures are found in Table S1 . 940 Finally, the QX200™ Droplet Digital™ PCR System (Bio-Rad) quantified the amount of miRNA 

Evaluation 1162 of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis

Application of methylene blue 1166 -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-1167 I clinical trial

Targeting glucose metabolism for treatment of COVID-19

COVID-19 Drug Discovery Using Intensive Approaches

Effects of N-acetylcysteine on lead-1174 exposed PC-12 cells

Efficacy and Safety of the mRNA

CoV-2 Vaccine

SARS-CoV-2 may regulate cellular responses through depletion of specific host 1180 miRNAs

ClueGO: a Cytoscape plug-in to decipher 1183 functionally grouped gene ontology and pathway annotation networks

Imbalanced Host Response to SARS-CoV-2 Drives 1187 Development of COVID-19

EnhancedVolcano: Publication-ready volcano plots 1189 with enhanced colouring and labeling

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Shotgun transcriptome, spatial omics, and 1195 isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, 1196 and drug interactions

Can pioglitazone be potentially useful 1198 therapeutically in treating patients with COVID-19? Med Hypotheses 140

Persistent 1200 Symptoms in Patients After Acute COVID-19

The Mitochondrial 1202

Acylome Emerges: Proteomics, Regulation by Sirtuins, and Metabolic and Disease Implications

Deregulated 1206 miRNA expression is associated with endothelial dysfunction in post-mortem lung biopsies of 1207 COVID-19 patients

miRNet 2.0: network-based visual analytics 1209 for miRNA functional analysis and systems biology

Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage 1212 cervical squamous cell carcinoma

miRDB: an online database for prediction of functional 1214 microRNA targets

Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1218 1alpha/Glycolysis-Dependent Axis

The GTEx Consortium atlas of genetic regulatory effects across human 1220 tissues

enhances T cell trafficking and antiviral effector function in a model of coronavirus-induced 1223 neurologic disease

STAR: ultrafast universal RNA-seq aligner

miRWalk2.0: a comprehensive atlas of microRNA-target 1227 interactions

Management of Unilateral Axillary 1229

Facile accelerated specific therapeutic (FAST) platform develops 1233 antisense therapies to counter multidrug-resistant bacteria

Identification of the novel 3' UTR sequences 1236 of human IL-21 mRNA as potential targets of miRNAs

MicroRNA 1238 targets in Drosophila

The nf-core framework for community-curated 1241 bioinformatics pipelines

Mitochondrial miRNA Determines Chemoresistance by

Regulating Mitochondrial Transcription

Data Analysis Reveals Tissue-specific Network Associated with SARS-CoV-2 Infection

Most mammalian mRNAs are 1249 conserved targets of microRNAs

Interpretable Drug Target 1251 Predictions using Self-Expressiveness. bioRxiv

ShinyGO: a graphical gene-set enrichment tool for animals 1253 and plants

Metronidazole; a Potential Novel 1255 Addition to the COVID-19 Treatment Regimen

Humoral 1258 Immune Response to SARS-CoV-2 in Iceland

Survival analysis across the entire transcriptome identifies biomarkers with 1260 the highest prognostic power in breast cancer

The roles of signaling 1264 pathways in SARS-CoV-2 infection; lessons learned from SARS-CoV and MERS-CoV

Modeling lung perfusion abnormalities 1267 to explain early COVID-19 hypoxemia

Glutathione and N-acetylcysteine suppression of human 1269 immunodeficiency virus replication in human monocyte/macrophages in vitro

Expression 1272 Profiling of Cellular MicroRNA in Asymptomatic HBsAg Carriers and Chronic Hepatitis B 1273 Patients

C1orf61 acts as a tumor activator in human hepatocellular carcinoma and is 1276 associated with tumorigenesis and metastasis

MiR-10a-5p-Mediated Syndecan 1 Suppression Restricts Porcine Hemagglutinating 1279

Clinical features of patients infected with 2019 novel coronavirus in

Severe 1284 acute kidney injury associated with progression of chronic kidney disease after critical COVID-1285 19

Therapeutic blockade of inflammation in severe COVID-19 infection with 1288 intravenous N-acetylcysteine

Viral miRNAs confer survival in host cells by 1290 targeting apoptosis related host genes

Persistence of symptoms and 1293 quality of life at 35 days after hospitalization for COVID-19 infection

Treatment of HCV infection by 1296 targeting microRNA

Prevention and mitigation 1298 of acute death of mice after abdominal irradiation by the antioxidant N-acetyl-cysteine

1301 miR2Disease: a manually curated database for microRNA deregulation in human disease

Animal and translational models of SARS-CoV-2 1305 infection and COVID-19

Modulation of 1307 hepatitis C virus RNA abundance by a liver-specific MicroRNA

The human genome browser at UCSC

pheatmap: Pretty heatmaps

Fast gene set enrichment analysis. bioRxiv

Sudden irreversible hearing loss post 1314 COVID-19

Transcriptome assembly from long-read RNA-seq alignments with StringTie2

miRBase: from microRNA 1319 sequences to function

Cutaneous Hyperaesthesia in SARS-CoV-1321 2 Infection: Rare but not Unique Clinical Manifestation

The Connectivity Map: using gene-expression 1324 signatures to connect small molecules, genes, and disease

Detection of elevated levels of tumour-1327 associated microRNAs in serum of patients with diffuse large B-cell lymphoma

Coronavirus breakthrough: dexamethasone is first drug shown to save lives

MiR-2392 suppresses metastasis and epithelial-mesenchymal transition by targeting MAML3 and 1333 WHSC1 in gastric cancer

Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age

SM2miR: a database of the experimentally validated small molecules' effects on microRNA 1339 expression

mtDNA Variation and Analysis Using Mitomap and Mitomaster

Moderated estimation of fold change and dispersion 1344 for RNA-seq data with DESeq2

Assembly of 1346 inflammation-related genes for pathway-focused genetic analysis

Patterns of known and novel small 1348 RNAs in human cervical cancer

The Coronavirus Transmissible Gastroenteritis Virus Evades the Type I Interferon Response 1351 through IRE1alpha-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis

A sobering addition to the literature on COVID-19 and the 1354 brain

COVID-19 Presenting as Banti's 1356 Syndrome

Diabetes and COVID-19 risk: an miRNA 1358 perspective

Circulating microRNAs as 1361 stable blood-based markers for cancer detection

Potential role of cellular miRNAs in coronavirus-host interplay

COVID-19 and 1365 cardiovascular disease: from basic mechanisms to clinical perspectives

Consensus transcriptional regulatory 1368 networks of coronavirus-infected human cells. Sci Data

In vitro antiviral activity and preclinical and clinical 1371 resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human 1372 factor miR-122

NASA GeneLab RNA-seq consensus 1375 pipeline: standardized processing of short-read RNA-seq data

Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection 1378 revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps. bioRxiv

Salmon provides fast 1381 and bias-aware quantification of transcript expression

Safety and Efficacy of the BNT162b2 mRNA 1384

Covid-19 Vaccine

The NF-kappaB-dependent and -independent transcriptome 1387 and chromatin landscapes of human coronavirus 229E-infected cells

Hepatic 1389 consequences of COVID-19 infection. Lapping or biting?

MitoCarta3.0: an updated mitochondrial proteome now 1392 with sub-organelle localization and pathway annotations

Transcriptionally Active Lung Microbiome and Its Association with Bacterial 1395 Biomass and Host Inflammatory Status

limma 1397 powers differential expression analyses for RNA-sequencing and microarray studies

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Nervous System: Implications 1401 of COVID-19 in Neurodegeneration

Protective role of statins in COVID 19 1403 patients: importance of pharmacokinetic characteristics rather than intensity of action

Hydroxychloroquine Inhibits 1407 the Trained Innate Immune Response to Interferons

MicroRNA therapeutics: towards a new era for the 1409 management of cancer and other diseases

Computational analysis of microRNA-mediated 1411 interactions in SARS-CoV-2 infection

Interim Results of a Phase 1-2a Trial of 1414

S Covid-19 Vaccine

Identification of Novel SARS-CoV-2 Drug Targets 1416 by Host MicroRNAs and Transcription Factors Co-regulatory Interaction Network Analysis

microRNA-122 amplifies hepatitis C virus translation by shaping the 1420 structure of the internal ribosomal entry site

Decline in SARS-CoV

Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital 1424 Network -12 States

Cytoscape: a software environment for integrated models 1427 of biomolecular interaction networks

Genomic Diversity of Severe Acute Respiratory Syndrome-Coronavirus 2 in Patients 1430

With Coronavirus Disease

GISAID: Global initiative on sharing all influenza data -from 1432 vision to reality

MetaOmGraph: a workbench for 1434 interactive exploratory data analysis of large expression datasets

The relationship between COVID-19 and the dental damage 1436 stage determined by radiological examination

Discovery and preclinical validation of drug indications using compendia of 1439 public gene expression data

SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or 1443 vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study

Multilevel proteomics reveals host perturbations by SARS-1446

A Mini-Review on Cell Cycle 1448 Regulation of Coronavirus Infection

Gene set enrichment 1451 analysis: a knowledge-based approach for interpreting genome-wide expression profiles

The COVIDome Explorer Researcher Portal. 1455 medRxiv

The noncoding and coding transcriptional landscape of the peripheral immune response in 1458 patients with COVID-19

MicroRNAs Bioinformatics Analyses Identifying HDAC Pathway as 1461 a Putative Target for Existing Anti-COVID-19 Therapeutics

Regulation of Hepatitis C Virus Genome Replication by Xrn1 and MicroRNA-122 Binding 1464 to Individual Sites in the 5' Untranslated Region

Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts 1467 human dendritic cell maturation

MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing

MicroRNA Regulation of RNA Virus Replication 1472 and Pathogenesis

Coronavirus biology and 1474 replication: implications for SARS-CoV-2

Safety, tolerability, and 1477 antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, 1478 randomised controlled trial

MiRmap: comprehensive prediction of microRNA target 1480 repression strength

Mitochondrial genetic medicine

Mitochondrial DNA in innate immune responses and 1483 inflammatory pathology

ggplot2: Elegant Graphics for Data Analysis

LncRNA CACNA1G-AS1 facilitates hepatocellular 1486 carcinoma progression through the miR-2392/C1orf61 pathway

miR-124 attenuates Japanese 1488 encephalitis virus replication by targeting DNM2

Is there an impact of the COVID-19 pandemic 1490 on male fertility? The ACE2 connection

Systemic lupus erythematosus 1492 manifestation following COVID-19: a case report

New mitochondrial DNA synthesis enables NLRP3 inflammasome 1495 activation

A Novel Coronavirus from Patients with Pneumonia in China

 949 Fastq files were downloaded from SRA (NCBI BioProject PRJNA605907 (Shen et al., 2020) 950 and NCBI BioProject PRJNA390194 (Ren et al., 2018) ). Fastq data files were trimmed using 951 TrimGalore v (0.6.4) with a quality cutoff of 30. Data were then aligned using STAR (v2.7.3) two 952 pass mode to the Human reference genome (GRCh38 v99 downloaded 04-27-2020). Unaligned 953 data were written to a fastq file, and then realigned to the GRCh38 reference genome using Bowtie 954 2 (v2.3.4.1), and output sam file converted to a bam file using samtools (v1.7). The resultant Bam 955 files were merged, sorted, and read groups added using picard tools (v2.21.3). 964 RNA isolation and library preparation is fully described in Butler, et al. (Butler et al., 2021) . 965 Briefly, library preparation on the all nasopharyngeal swab samples' total nucleic acid (TNA) were 976 RNA isolation and library preparation is fully described in Park, et al. (Park et al., 2021) . 977 Briefly, autopsy tissues were collected from lung, liver, lymph nodes, kidney, and the heart and 978 were placed directly into Trizol, homogenized and then snap frozen in liquid nitrogen. At least 979 after 24 hours these tissue samples were then processed via standard protocols to isolate RNA. 1003 The Nanoligomer platform was used to design Nanoligomer inhibitors, which are composed were displayed using pheatmap (Kolde, 2015) . Volcano plots were made use R program 1035 EnhancedVolcano (Blighe et al., 2018) .

Analysis of Autopsy RNA-seq data 1038 The full methods of the analysis from the autopsy patients is currently available in the Park et 1039 al. (Park et al., 2021) . Briefly, RNA-seq data was processed through the nf-core/rnaseq pipeline 1055 To combine the results from the autopsy and nasopharyngeal swab RNA-seq data, we utilized 1056 the t-score values from the DESeq2 analysis. Heatmaps were displayed using pheatmap (Kolde, 1057 2015). 1060 For pathway analysis on the miR-2392 targets (Fig. 3) 1070 For the analysis of the miR-2392 targets in the blood tissue, we downloaded whole blood COVID-19 status", Platform "Blood", Statistical test "Student's t-test", Adjustment method "none", 1074 Sex "male" and "female", Age Group "All". For Proteome data we used the following filters:

Category "Effect of COVID-19 status", Platform "SOMAscan", Statistical test "Student's t-test", 1076 Adjustment method "none", Sex "male" and "female", Age Group "All". We created the list of the 1113 To explore potential binding sites for miR-2392 we used miRanda software (Enright et al., 1114 2003) to identify all potential binding sites with respect to the SARS-CoV-2 reference genome 1115 (Wuhan-Hu-1; NC045512.2) and representative genomes from lineages of concern. The lineages 1116 of concern were selected from Global Initiative on Sharing All Influenza Data (GISAID) with each